Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.65 |
| ▸ | NPY4R | P50391 | 11/20 | 0.65 |
| ▸ | NPY1R | P25929 | 9/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.65 |
| ▸ | NPY2R | P49146 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21483092 | 1.00 | OPRD1 (0.65) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29657682 | 1.00 | OPRD1 (0.65) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL10785712 | 1.00 | OPRD1 (0.65) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL26689635 | 1.00 | OPRD1 (0.65) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL1917250 | 1.00 | OPRD1 (0.65) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| Acetic Acid SCHEMBL29959250 | 0.99 | OPRD1 (0.64) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29958878 | 0.99 | NPY4R (0.66) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| Acetic Acid SCHEMBL30708944 | 0.98 | NPY4R (0.65) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL30932462 | 0.95 | NPY4R (0.66) | OPRD1OPRM1OPRK1NPY4RNPY1R | |
| SCHEMBL29959235 | 0.95 | NPY4R (0.71) | OPRD1OPRM1OPRK1NPY4RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365216-B2 | Antiviral immunotropic agent for the treatment of acute respiratory viral infections | PVP LABS PTE. LTD. (SG) | 2022-06-21 | — | — | US | claimed |
| EP-3622964-B1 | AGENT FOR THE TREATMENT OF SKIN WOUNDS OR BURNS | PVP LABS PTE LTD (SG) | 2022-03-30 | — | — | EP | claimed |
| WO-2021224664-A1 | APPLICATION OF DALARGIN FOR THE PREVENTION OF VRIS AND PREVENTION OF THE DEVELOPMENT OF COMPLICATIONS DURING VRIS | PVP LABS PTE. LTD. (SG) | 2021-11-11 | — | — | WO | claimed |
| US-20210346459-A1 | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs | PVP LABS. PTE. LTD (SG) | 2021-11-11 | — | — | US | claimed |
| EP-3906934-A1 | APPLICATION OF DALARGIN FOR THE PREVENTION OF VIRAL RESPIRATORY INFECTIONS AND PREVENTION OF THE DEVELOPMENT OF COMPLICATIONS DURING VIRAL RESPIRATORY INFECTIONS | PVP Labs PTE. Ltd. (SG) | 2021-11-10 | — | — | EP | claimed |
| EP-3556377-B1 | DALARGIN FOR USE IN THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS | PVP LABS PTE LTD (SG) | 2021-09-08 | — | — | EP | claimed |
| US-20210161993-A1 | Method for accelerated healing of burn wounds | PVP LABS PTE. LTD. (SG) | 2021-06-03 | — | — | US | claimed |
| CN-112020367-B | Antiviral immunomodulator for treating acute respiratory infectious diseases | PVP 实验室私人有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-112689514-A | A therapeutic agent for skin injury or burn | PVP 实验室私人有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-112020367-A | Antiviral immunomodulator for treating acute respiratory infectious diseases | PVP 实验室私人有限公司 | 2020-12-01 | — | — | CN | claimed |
| EP-3622964-A1 | AGENT FOR THE TREATMENT OF SKIN WOUNDS OR BURNS | PVP Labs PTE. Ltd. (SG) | 2020-03-18 | — | — | EP | claimed |
| US-20200078438-A1 | Agent for the Treatment of Skin Wounds or Burns | PVP LABS PTE. LTD. (SG) | 2020-03-12 | — | — | US | claimed |
| US-20190322701-A1 | Antiviral Immunotropic Agent for the Treatment of Acute Respiratory Viral Infections | PVP LABS PTE. LTD. (SG) | 2019-10-24 | — | — | US | claimed |
| WO-2019202380-A1 | ANTIVIRAL IMMUNOTROPIC AGENT FOR THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS | PVP LABS PTE. LTD (SG) | 2019-10-24 | — | — | WO | claimed |
| EP-3556377-A1 | ANTIVIRAL IMMUNOTROPIC AGENT FOR THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS | PVP Labs PTE. Ltd. (SG) | 2019-10-23 | — | — | EP | claimed |
| EP-3906934-B1 | APPLICATION OF DALARGIN FOR THE PREVENTION OF VIRAL RESPIRATORY INFECTIONS AND PREVENTION OF THE DEVELOPMENT OF COMPLICATIONS DURING VIRAL RESPIRATORY INFECTIONS | PVP LABS PTE LTD (SG) | 2024-09-25 | — | — | EP | disclosed |
| US-11365216-B2 | Antiviral immunotropic agent for the treatment of acute respiratory viral infections | PVP LABS PTE. LTD. (SG) | 2022-06-21 | — | — | US | disclosed |
| US-20190322701-A1 | Antiviral Immunotropic Agent for the Treatment of Acute Respiratory Viral Infections | PVP LABS PTE. LTD. (SG) | 2019-10-24 | — | — | US | disclosed |
| EP-3556377-A1 | ANTIVIRAL IMMUNOTROPIC AGENT FOR THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS | PVP Labs PTE. Ltd. (SG) | 2019-10-23 | — | — | EP | disclosed |
| EP-3556377-A1 | ANTIVIRAL IMMUNOTROPIC AGENT FOR THE TREATMENT OF ACUTE RESPIRATORY VIRAL INFECTIONS | PVP Labs PTE. Ltd. (SG) | 2019-10-23 | — | — | EP | disclosed |